Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735729 | 0.91 | PRKCA (0.39) | PRKCAMMP12ALDH1A1OPRM1OPRD1 | |
| SCHEMBL1980728 | 0.89 | SCN9A (0.42) | PRKCAMMP12CYP3A4CYP2C19NR1I2 | |
| SCHEMBL1980990 | 0.85 | PTGDR2 (0.41) | PRKCAMMP12CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1956565 | 0.85 | PRKCA (0.48) | PRKCAMMP12ALDH1A1MEN1KMT2A | |
| SCHEMBL1956510 | 0.84 | PLA2G1B (0.38) | PRKCAMMP12ALDH1A1OPRM1OPRD1 | |
| SCHEMBL1981685 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL1980881 | 0.78 | SCN9A (0.48) | PRKCAMMP12ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL1981129 | 0.78 | PRKCA (0.37) | PRKCAMMP12CYP3A4CYP2C19NR1I2 | |
| SCHEMBL1954406 | 0.77 | PRKCA (0.37) | PRKCAMMP12ALDH1A1OPRM1OPRD1 | |
| SCHEMBL752222 | 0.74 | NR1I2 (0.54) | PRKCAMMP12ALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102124012-B | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARM LTD | 2014-07-02 | — | — | CN | disclosed |
| EP-2331554-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN R & D IRELAND (IE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2331554-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN R & D IRELAND (IE) | 2013-03-06 | — | — | EP | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| CN-102124012-A | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARM LTD | 2011-07-13 | — | — | CN | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| WO-2010018233-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, IDO2, ZC3HAV1 | PRKCA 3816/4885MMP12 3986/4885ALDH1A1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.